# HPV16 E6 TCR T Cells for Cervical Carcinoma

> **NCT05357027** · PHASE1,PHASE2 · TERMINATED · sponsor: **TCRCure Biopharma Ltd.** · enrollment: 5 (actual)

## Conditions studied

- Cervical Carcinoma

## Interventions

- **BIOLOGICAL:** TC-E202 cells
- **DRUG:** IL-2
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide Capsules

## Key facts

- **NCT ID:** NCT05357027
- **Lead sponsor:** TCRCure Biopharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-10
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-01-15
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs
- **Last updated:** 2026-01-21

## Collaborators

- Fudan University

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357027, "HPV16 E6 TCR T Cells for Cervical Carcinoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05357027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*